The Conafay Group
Marily Rhudy has a diverse work history that spans over three decades. Marily began their career as the Chairman of the Board and President of the American Pharmaceutical Association in 1983 and held various roles over a ten-year period. Rhudy later worked as a Member of the Heath Professionals Review Group at The White House in 1993. In the same year, they started working at Wyeth, where they served as a Senior Vice President of Corporate Public Affairs from 1993 to 2008.
In 2008, Rhudy started their consulting firm, MHR Consulting, where they acted as a Principal. In 2009, they began working at Talecris Biotherapeutics as a Senior Vice President and served until 2011. Marily later joined Nanotherapeutics, Inc., where they worked as a Director starting in 2014 until 2017.
Finally, Rhudy joined the Conafay Group in 2013 as the Executive Vice President, a role that they currently hold. Throughout their career, Rhudy has held various leadership roles, and their work history showcases their experience in corporate public affairs, health care reform, and consulting.
Marily Rhudy earned a Bachelor of Science degree in Pharmacy from The University of Kansas between 1968 and 1972.
The Conafay Group
The Conafay Group works with life science companies and organizations to develop and implement government funding and public policy strategies. We also bridge ties to philanthropic, non-‐profit, academic and commercial entities to enhance client outcomes. Working on behalf of our clients, we create and execute dynamic strategies that facilitate: • Non-Dilutive Funding • Health Policy Advocacy • Ally Development • Federal Government Relations • Public-Private Partnerships • Federal Marketing • Coalition Management • Business-to-Business Partnering TCG specializes in representing biomedical technologies and therapeutics before the federal government and associated stakeholders. Our client successes involve for-profit and non-profit entities in areas of funding, research and public policy. We identify and target novel funding opportunities, synergies between client technology and federal/private needs, and policy issues that affect life sciences companies. Our expertise provides our clients an advantage over competitors in the federal and non-federal funding market. Since 2003, our team has helped clients secure nearly $1B in non-dilutive funding and services. Led by Stephen Conafay, TCG is a team of engineers, scientists, and policy experts, as well as former industry executives and federal staff, who offer a wealth of scientific and policy expertise in issues relevant to the life sciences and biotechnology industry. Applying this collective expertise, we have an intimate understanding of the non-dilutive funding landscape, healthcare and innovation policy, federal government needs and priorities, and commercial/institutional partnering opportunities. Our strength lies in putting this knowledge, and our familiarity with the science behind our clients’ technology, to work for our clients. Through our team‐based approach, we are able to deliver fully integrated government relations strategies that enable our clients to achieve greater success.